FDA Clearance Tracker · P170019-S037
FoundationOne CDx
Last checked: Nov 20, 2026Latest source record: May 26, 2023 (this decision)Source: openFDAMethods & limitations
Decided
May 26, 2023
Approved
Time to decision
287 days
Received Aug 12, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170019-S037
- Device name
- FoundationOne CDx
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- Aug 12, 2022
- Decided
- May 26, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P170019
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the clinical protocol entitled Statistical Analysis Plan for Real-World Evidence Study Supporting FoundationOne®CDx as a Companion Diagnostic for Entrectinib in Non-Small Cell Lung Cancer Patients with ROS1 Fusions
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.